



Saliva-based COVID-19 detection: A rapid antigen test of SARS-CoV-2 nucleocapsid protein using an electrical-double-layer gated field-effect transistor-based biosensing system

Pin-Hsuan Chen^{a,1}, Chih-Cheng Huang^{b,1}, Chia-Che Wu^b, Po-Hsuan Chen^b, Adarsh Tripathi^c, Yu-Lin Wang^{a,b,*}

^a Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu 300044, Taiwan (R.O.C.)

^b Institute of Nanoengineering and Microsystems, National Tsing Hua University, Hsinchu 300044, Taiwan (R.O.C.)

^c Institute of Molecular Medicine, National Tsing Hua University, Hsinchu 300044, Taiwan (R.O.C.)

ARTICLE INFO

Keywords:

Covid-19
SARS-CoV-2
Electrical double layer
Field-effect transistor-based biosensors
Rapid antigen tests

ABSTRACT

Facing the unstoppable surges of COVID-19, an insufficient capacity of diagnostic testing jeopardizes the control of disease spread. Due to a centralized setting and a long turnaround, real-time reverse transcription polymerase chain reaction (real-time RT-PCR), the gold standard of viral detection, has fallen short in timely reflecting the epidemic status quo during an urgent outbreak. As such, a rapid screening tool is necessitated to help contain the spread of COVID-19 amid the countries where the vaccine implementations have not been widely deployed. In this work, we propose a saliva-based COVID-19 antigen test using the electrical double layer (EDL)-gated field-effect transistor-based biosensor (BioFET). The detection of SARS-CoV-2 nucleocapsid (N) protein is validated with limits of detection (LoDs) of 0.34 ng/mL (7.44 pM) and 0.14 ng/mL (2.96 pM) in 1× PBS and artificial saliva, respectively. The specificity is inspected with types of antigens, exhibiting low cross-reactivity among MERS-CoV, Influenza A virus, and Influenza B virus. This portable system is embedded with Bluetooth communication and user-friendly interfaces that are fully compatible with digital health, feasibly leading to an on-site turnaround, an effective management, and a proactive response taken by medical providers and frontline health workers.

1. Introduction

As the new hotspots were hit by the unstoppable surges of COVID-19 [1], the reported cases have surpassed 208 million worldwide as of August 2021 [2]. COVID-19, an ongoing pandemic with fast-evolving variants, is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerging as the most impactful threat to global health in a century [3]. The cumulative death toll has reached over 4.3 million since the outbreak was declared by the World Health Organization (WHO) in 2020 [2]. Early symptoms of COVID-19 are similar to a common flu-like illness; yet in serious cases, patients may suffer dyspnea and proceed with severe pneumonia, acute respiratory distress, multiple organ dysfunction, septic shock, etc. [4]. Vaccination, which reduces the risk of severe COVID-19 [5,6], is regarded as the most effective tool against the viral transmission; whereas the treatments remain unclear

and mostly rely on supportive care [7,8]. As such, rapid detection, effective management, and proactive responses are necessitated to contain the spread of COVID-19 across the countries where vaccine implementations have not been widely deployed.

COVID-19 diagnostics can be sorted into two categories [9]: viral tests (also known as diagnostic test) and antibody tests. Viral tests, such as molecular tests (for viral RNA) and antigen tests (for viral protein), diagnose active infection of patients; while antibody tests are serological tests reflecting past infection [10]. The real-time reverse transcription polymerase chain reaction (real-time RT-PCR), the gold standard for SARS-CoV-2 viral tests, is an *in vitro* diagnostics (IVDs) where a sample is usually collected through a nasal swab [11,12]. This nucleic acid-based testing can detect as low as ~100 copies/mL of the viral RNA [13], but its sensitivity varies from 70% (real-world tests) to 99% (an ideal condition) [14–17]. The turnaround time of a real-time RT-PCR test usually

* Corresponding author at: Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu 300044, Taiwan (R.O.C.).

E-mail address: ylwang@mx.nthu.edu.tw (Y.-L. Wang).

¹ These authors contributed equally to this work.

takes from 4 h to 2 days, and it needs to be operated by highly skilled personnel in a centralized lab [18].

Several rapid antigen testing techniques were approved of Emergency Use Authorizations (EUA) by the U.S. Food and Drug Administration (FDA) [19,20]. A lateral flow immunochromatographic assay (LFIA) provides a qualitative detection for COVID-19 [21,22], while a chemiluminescence enzyme immunoassay (CLEIA) offers a quantitative measurement of SARS-CoV-2 antigens [23]. Compared to PCR-based techniques, the testing time of a viral antigen detection is tremendously reduced (within 60 min) [16,22]. However, the sensitivity is usually compromised (60 – 80%) [22,23], and the semi-invasive specimen collection using nasal, nasopharyngeal, or oropharyngeal swabs brings discomfort to testees. As such, a salivary detection, which avails a noninvasive sample collection, has been considered as an alternative method for rapid COVID-19 screenings. Moreover, viral loads found in saliva, ranging from 10^4 copies/mL to 10^8 copies/mL, are comparable with what are found in nasal cavities and throats [24–30]. Amongst novel antigen tests developed for COVID-19 [16,22,23,31], field-effect transistor-based biosensors (BioFET) are of significant advantages as per a high sensitivity, a wide dynamic range, a real-time readout, and a matrix-insensitivity across a wide variety of analytes [31–41]. Nanomaterial-based BioFETs demonstrate the excellent candidacy for low-concentration measurements [31,35,38]. BioFETs using high electron mobility transistors (HEMTs) are utilized to detect miRNA [37], peptide [33,39], SARS-CoV-1 nucleocapsid (N) protein [34], circulating tumor cells (CTCs) [40], etc. Though the reported BioFETs using nanomaterials [31,32,35,38,41] or HEMTs [33,34,37,39,40] are highly sensitive, their costs, reusability, and portability must be improved before deploying for *in situ* COVID-19 immunoassays. As such, a portable BioFET featuring low cost, disposable testing sticks, good sensitivity, and salivary detection should be developed to address the needs for on-site COVID-19 screenings.

In this work, we developed a saliva-based antigen test of SARS-CoV-

2 N protein using an electrical double layer (EDL)-gated BioFET system (Fig. 1). The proposed system included a portable reader functioned with Bluetooth where a testing result can be immediately displayed on a smartphone using mobile-based user interface (UI). The ease of pre-treatment and the digital health-compatible setting enabled a fast turnaround time (within 30 min). EDLs were redistributed along with reactions on surfaces, and the changes in EDL capacitance allowed BioFETs to detect analytes in a variety of physiological conditions (e.g., serum, blood, saliva, etc.) [32,42]. Surface functionalization was verified with fluorescence imaging, and sensor-to-sensor variation is discussed. The COVID-19 antigen tests using EDL-gated BioFETs were validated in both $1 \times$ PBS and artificial saliva, and the limits of detection (LoDs) were calculated. To investigate cross-reactivity, the antigens of MERS-CoV, Influenza A virus, and Influenza B virus were tested. Aiming to find a diagnostic niche, the antigen tests in artificial saliva using an EDL-gated BioFET can progress toward the detection of clinical samples (human saliva). This rapid testing can timely reflect the epidemic status quo (e.g., the number of infected individuals) and benefit the policy-making, fighting against the spread of COVID-19.

2. Materials and methods

2.1. The BioFET system for COVID-19 viral antigen tests

The custom-designed BioFET platform, as shown in Fig. 1 and Supplemental Fig. 1, consisted of a disposable sensor stick, a portable reader (CC&C Technologies, Taiwan) embedded with a Bluetooth function, and two custom-written UIs operated for Microsoft Windows and iOS, respectively. Each sensor stick (Jumpers Biotech, Taiwan), which was custom-designed and fab-manufactured, had 8 individually addressable sensors arranged in an 1×8 array where each sensor comprised of two gold electrodes ($500 \times 500 \mu\text{m}^2$) on a $75\text{-}\mu\text{m}$ pitch. SU-8 photoresist (Kayaku Advanced Materials, #SU8–2010) was coated on a sensor stick,




Fig. 1. Schematic illustration of a saliva-based COVID-19 antigen test using an electrical double layer (EDL)-gated field-effect transistor biosensor (BioFET). An artificial saliva sample consisting of SARS-CoV N protein is drop-casted on a sensor stick, and a testing result is displayed on a smart phone via Bluetooth in 30 min.

and an active area ($450 \times 450 \mu\text{m}^2$) of each electrode was photolithographically defined. An input gate voltage (V_g) was applied on one of the electrodes (of each sensor), and an output V_g was measured at the gate terminal of an FET via the other electrode (of each sensor). The Bluetooth-embedded reader transmitted data to the devices where a real-time result was displayed on an iPhone, and raw data were stored in a laptop for further analysis.

2.2. Surface functionalization

A sensor stick was placed in an O_2 plasma cleaner (Harrick Scientific Products, USA, #PDC-32G) for 180 s at a constant power of 18 W (high RF level), then the sensor stick was rinsed with 10% HCl (Sigma-Aldrich, #320331) and DI water, successively. The anti-SARS-CoV-2 N protein antibody (GeneTex, Taiwan, #GTX632269), simply named “anti-N antibody” throughout the rest of content, was used as the capture antibody. 14 mM of Traut’s Reagent (Thermo Fisher Scientific, #26101) was dissolved in PBS-EDTA ($1 \times$ PBS, with 5 mM of EDTA) prior to mixing with 1.5 mg/mL of anti-N antibody (volume ratio = 1:10) at room temperature for 1 h. 11 μL of thiolated antibody, formed through the previous procedure, was detached from an excess amount of Traut’s Reagent using a desalting column (Thermo Fisher Scientific, #89877) which was equilibrated with PBS-EDTA. The thiolated antibody was diluted with PBS-EDTA at a volume ratio of 1 : 1, and the final concentration was 0.68 mg/mL. 0.5 μL of diluted antibody solution was then drop-casted on each sensor where the immobilization took place at $14 - 18^\circ\text{C}$ for 12 h. Finally, the functionalized sensors were rinsed with 1 mL of $1 \times$ PBS to remove the unbound antibody.

2.3. Fluorescence imaging

Anti-Mouse IgG (GeneTex, Taiwan, #GTX213111-05), the secondary antibody bound to the capture antibody (anti-N antibody), was labeled with a fluorescent dye (DyLight 594). 50 μL of the solution, in the presence of fluorophore-labeled antibody (2 $\mu\text{g}/\text{mL}$), was drop-casted on a sensor stick (covering all the eight sensors) and incubated at room temperature for 1 h. Afterwards, the sensor stick was rinsed with 1 mL of $1 \times$ PBS and the unbound fluorophore-labeled antibody was removed. An optical measurement was taken by a fluorescence microscope (Leica Microsystems, #DM2500 LED) where a result was analyzed and quantified using Leica LAS X and Image J.

2.4. Proteins and immunoassays

In PBS-based immunoassays, the desired concentrations of SARS-CoV-2 N protein (GeneTex, Taiwan, #GTX135357-pro), SARS-CoV-2 S protein (Leadgene Biomedical, Taiwan, #61831), MERS-CoV N protein (GeneTex, Taiwan, #GTX135653-pro), Influenza A virus nucleoprotein (GeneTex, Taiwan, #GTX135868-pro), and Influenza B virus nucleoprotein (GeneTex, Taiwan, #GTX135867-pro) were respectively spiked into $1 \times$ PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na_2HPO_4 , and 2 mM KH_2PO_4 at $\text{pH} = 7.4$ with NaOH). In saliva-based immunoassays, 100 μM of sodium dodecyl sulfate (SDS) (Thermo Fisher Scientific, #28312) was dissolved in clinically mimetic matrix where artificial saliva (Pickering Laboratories, USA, #1700-0305) was mixed with the universal transport medium (UTM) (COPAN Diagnostics, USA, #330 C) at a volume ratio of 1:1. The mixture of artificial saliva, SDS, and UTM, is simply named as “artificial saliva” throughout the rest of content. Following the same procedures, the desired concentrations of SARS-CoV-2 N protein, SARS-CoV-2 S protein, MERS-CoV N protein, Influenza A virus nucleoprotein, and Influenza B virus nucleoprotein were respectively spiked into artificial saliva. Both kinds of immunoassays were performed in the presence of capture probes (anti-N antibody) which were immobilized on a sensor surface. 70 μL of a testing solution was drop-casted on a sensing area, and signals were measured/recorded using the custom-designed BioFET platform.

2.5. FET characteristics and signal acquisition

N-channel depletion-mode DMOS FETs (Microchip Technology, #LND150) ($n = 8$) were electrically characterized by a semiconductor parameter analyzer (Agilent, #B1500A) prior to mounting on a printed circuit board (PCB) (Supplemental Fig. 1). The transfer characteristics of the FET are shown in Fig. 2a, the maximum transconductance takes place near $V_g = 0$ V at a constant source-drain voltage (V_d) of 2 V. The FET characteristics of drain current (I_d) versus V_d are displayed in Fig. 2b.

The COVID-19 antigen tests were taken at a constant V_d (2 V) with a square wave of gate biases ($V_g = 0$ V for 2 ms followed by $V_g = 1$ V for 2 ms) as shown in Fig. 2c. The elapsed time of each measurement was set as 212 ms where three pulses of V_g were applied discretely with two intermediate turnoffs. The output I_d was measured at a sampling rate of 167 kHz, and I_{ch} was the characteristic current at which the difference between two current levels was calculated:

$$I_{ch} = \overline{I_{d,1}} - \overline{I_{d,0}}, \quad \text{with} \quad (1)$$

$$\overline{I_{d,0}} = \sum_{n=1}^3 \overline{I_{d,0V(n)}} \quad \text{and} \quad (2)$$

$$\overline{I_{d,1}} = \sum_{n=1}^3 \overline{I_{d,1V(n)}} \quad (3)$$

where $\overline{I_{d,0V(n)}}$ is the averaged I_d calculated within the last 1 ms of the n th pulse at $V_g = 0$ V, and $\overline{I_{d,1V(n)}}$ is the averaged I_d calculated within the last 1 ms of the n th pulse at $V_g = 1$ V.

3. Results and discussion

The BioFET platform adopted the outreach configuration, where gate terminals of the FETs were extended via wires and connected to a sensor stick, to prevent direct corrosion of a testing sample on FETs. To overcome the Debye screening while enabling detection in a physiological condition (e.g., serum, blood, saliva, etc.), EDL-gated BioFETs were leveraged to measure double-layer capacitance rather than surface charges. As such, sample pretreatment can be tremendously eased, and a turnaround time is significantly reduced (<1 h) [32,37,39,40,42]. The detailed sensing mechanism using an EDL-gated BioFET can be found in Supplemental Fig. 2.

To amplify an electrical signal, the FETs measured a testing sample at a linear region ($V_g = 1$ V) and a saturation region ($V_g = 0$ V), respectively (as described in Materials and Methods). A high V_d causes a heating effect that gives rise to a noisy background and a signal drift, yet a low V_d yields a small transconductance. As a trade-off, V_d was set as 2 V to achieve a higher conductance (compared to $V_d = 1$ V) while producing a minor heating and an acceptable noise. The data were retrieved and collected every 2 min, and totally 11 measurements (20 min) were taken for each concentration of analytes.

3.1. Surface functionalization

To confirm successful surface functionalization, a fluorescent measurement was performed. A sensor stick was split into two groups: three (out of eight) sensors were treated with buffer solution, serving as the control group; while the other five sensors were functionalized with capture antibody, serving as the experiment group. After incubation of fluorophore-labeled secondary antibody, the optical tags (i.e., fluorophores) were excited at 593 nm and emitted red fluorescence at 618 nm. A mean fluorescence intensity (MFI) was quantified within a quarter of an electrode using ImageJ, and 8 subareas were measured for a sensor. The background induced 14.08 ± 0.05 A.U. of MFI prior to incubation of secondary antibody as shown in Supplemental Fig. 3. In the control group, a minor amount of the secondary antibody remained on the surface after the washing step, emitting 18.49 ± 1.16 A.U. of




Fig. 2. (a) Transfer characteristics, and (b) I_d - V_d characteristics at different gate biases of a FET. (c) Signal acquisition. The inputs were applied with a constant V_d and three pulses of V_g during each measurement, while the output signals (I_{ch}) were retrieved by the difference between two current levels.

MFI. While the experiment group exhibited at least 28.40 A.U. of MFI (Supplemental Fig. 3). The representative images of an unfunctionalized sensor (S#1) and a functionalized sensor (S#4) are shown in Fig. 3, and the brightness indicates the amount of the fluorophore-labeled secondary antibody. The relative MFI (R. MFI) was defined as the ratio of an MFI measured after incubation of secondary antibody to an MFI measured before incubation of secondary antibody ($R. MFI \equiv \frac{MFI_{after\ incubation}}{MFI_{before\ incubation}}$). Error bars represent one standard deviation (1σ) of uncertainties measured across sensors as shown in Fig. 3 ($n = 5$ in the experiment group, $n = 3$ in the control group). The experiment group exhibited $2\times$ the R.MFI of the control group, indicating a successful functionalization that can be employed for the succeeding immunoassays. While the sensor-to-sensor variation of R. MFI can be attributed to nonuniform immobilization of capture antibody.

3.2. Saliva-based COVID-19 antigen tests using BioFETs

The structural proteins of SARS-CoV-2 are majorly composed of envelope (E) protein, transmembrane (M) protein, N protein, and spike (S) protein. N protein is abundantly expressed during an infection, thus it is regarded as a highly immunogenic protein and was selected for the antigen tests in this work [43]. To investigate the sensor response to SARS-CoV-2 viral protein; the desired concentrations of SARS-CoV-2 N protein, ranging from 0.4 ng/mL to 400 ng/mL, were prepared in $1\times$ PBS. The testing samples were drop-casted onto a sensor stick

successively varying from lowest to highest concentration, and electrical measurements were taken every two minutes using BioFETs. Prior testing sample was removed from the sensor stick before the next testing sample was added. A baseline of each series of measurement was defined as where a norm measurement was first taken in the absence of an analyte (N protein), and the subsequent BioFET signals were measured with a subtracted baseline:

$$\text{BioFET signal} \equiv \Delta I_{ch} = I_{ch,j} - I_{ch,0}, \quad (4)$$

where $I_{ch,j}$ is the I_{ch} measured at $[N \text{ protein}] = j \text{ ng/mL}$, and $I_{ch,0}$ is the I_{ch} measured at $[N \text{ protein}] = 0 \text{ ng/mL}$. BioFET measurements usually took several minutes to get signal stabilized after spiking analytes (due to temperature drift, diffusion, binding kinetics, etc.), so 8 out of 11 measurements were used to calculate a mean signal at each concentration.

In the controlled experiment, reference sensors were tested in the absence of an immobilized antibody (anti-N antibody), and the increasing concentrations of viral N protein had an unremarkable effect on a sensor response (variation $< 3 \mu A$) as shown in Fig. 4a. This indicates that non-specific binding was negligible. While the active sensors, immobilized with capture antibody, linearly responded to the added SARS-CoV-2 N protein (in a logarithmic scale) that the concentrations ranged from 0.4 ng/mL to 400 ng/mL. The sensor-to-sensor variation, as shown in Supplemental Fig. 4, may result from a nonuniform coverage of capture antibody (Fig. 3). To benchmark the sensor performance and quantify a LoD, the method of the Clinical and




Fig. 3. Optical quantification of surface functionalization (left) and fluorescent images (right). The relative mean fluorescence intensity (R. MFI) was calculated by the MFI measured before/after incubation of secondary antibody. The control group exhibits 2.62 A.U. of R. MFI. Error bars represent 1σ of sensor-to-sensor uncertainty measured by fluorescence intensity.




Fig. 4. COVID-19 antigen tests using EDL-gated BioFETs in (a) 1× PBS and (b) artificial saliva. Active sensors were functionalized with capture antibody, while reference sensors were unfunctionalized. SARS-CoV-2 N protein concentration varied from 0.4, 4, 40, to 400 ng/mL. Error bars represent ± 1σ of uncertainty measured by sensors ($n = 3$).

Laboratory Standards Institute (CLSI) was adopted [44,45]:

$$LoD = LoB + 1.645 \times \sigma_{low\ conc}, \quad \text{with} \quad (5)$$

$$LoB = mean_{blank} + 1.645 \times \sigma_{blank}, \quad (6)$$

where LoB is the limit of blank, $\sigma_{low\ conc}$ is the standard deviation of the result measured from the low concentration sample, $mean_{blank}$ is the mean result of the blank sample, and σ_{blank} is the standard deviation of the result measured from the blank sample. The overall change in signal was 22.0 μA, and the calculated LoD was 342.16 pg/mL (7.44 pM).

To validate COVID-19 antigen tests using BioFETs in a more realistic scenario, the measurements were taken in artificial saliva (as described in **Materials and Methods**). Saliva is viscous and tends to coagulate quickly after collection, making it difficult to be pipetted for further liquid-based measurements. As such, UTM was used to mix with artificial saliva due to its stability at room temperature when collecting as well as transporting viral samples [46,47]. Plus, the detergent (SDS), which can break a coat of the enveloped virus by denaturing a viral membrane or causing a conformational change, was added [48].

Following the same procedure of the PBS-based immunoassay, only the medium was replaced with artificial saliva. The reference sensors exhibited signal variations less than 5 μA (Fig. 4b), and the use of artificial saliva induced an opposite change in capacitance compared to what was measured in 1× PBS. In the experiment group, the overall change in signal was 46.33 μA with a good linearity ($R^2 = 0.998$), and the calculated LoD was 136.25 pg/mL (2.96 pM). The change of matrices exhibited comparable LoDs, and an addition of detergent (SDS) did not interfere with the assay. While an one-fold increase in the overall signals might be a consequence of inhomogeneous surface functionalizations and different media. The real-time results of COVID-19 antigen tests, in both 1× PBS and artificial saliva, can be found in [Supplemental Fig. 5](#). Considering a small volume (500 nL per sensor) used in surface functionalization, experimental uncertainty (e.g., manual pipetting) led to inhomogeneous surface coverages. In addition, biological complexity in artificial saliva brought on electrical fluctuation more formidably than in PBS. Overall, the testing time of each concentration was 20 min, and the turnaround time was less than 30 min, effectuating rapid COVID-19 antigen tests using an EDL-gated BioFET.

3.3. Investigation of cross-reactivity

To further inspect the specificity, various antigens were tested with EDL-gated BioFETs. SARS-CoV-2 S protein, MERS-CoV N protein, Influenza A virus nucleoprotein, and Influenza B virus nucleoprotein were spiked into artificial saliva, drop-casted on a sensor stick where its sensor surfaces were functionalized with anti-N antibody. The data of SARS-CoV-2 N protein shown in Fig. 5 are extracted from Fig. 4, enabling a visual comparison of the cross-reactivity. Among the groups of the lowest testing concentration (0.4 ng/mL), the specificities are relatively insignificant in both matrices. Notably, the signals of different antigens (except SARS-CoV-2 N protein) were located within the variations which were 3 μ A for PBS and 5 μ A for artificial saliva, respectively; and no increasing/decreasing trend was found in all cases. The detection specificities improved as the concentrations of antigens increased (>4 ng/mL), and SARS-CoV-2 N protein eventually achieved $11.21 \times$ the signal of other antigens at a concentration of 400 ng/mL in PBS. While the measurements in artificial saliva yielded signal-to-cross-reactivity ratios ($\frac{\text{Signal}_{\text{SARS-CoV-2N}}}{\text{Signal}_{\text{max among other antigens}}}$) of 4.04, 8.73, and 21.03 at concentrations of 4 ng/mL, 40 ng/mL, and 400 ng/mL, respectively. Though the higher signals were found in artificial saliva, the detection uncertainty was more significant in artificial saliva than PBS. This phenomenon can be attributed to the extra electrolytes and chemicals which may complicate the molecular environment. Taken together, EDL-gated BioFETs demonstrated good specificities (signal-to-cross-reactivity ratio > 4.04) in both PBS and artificial saliva when antigen concentrations were higher than 4 ng/mL, indicating a negligible cross-reactivity.

3.4. Testing landscape and comparison of COVID-19 diagnostics

As of August 2021, low vaccination rates and insufficient capacity of diagnostic testing have fueled the new cases of COVID-19 worldwide. To fight against the spread of COVID-19, a critical solution is to field diagnostic tools which have a high accuracy, a fast turnaround, a portable configuration, an user-friendly operation/readout delivering quantitative results, and a digital health-compatible setting [16,49]. Several proposed tools have received EUA [19,20,50], yet the governmental action primarily relies on the reported cases confirmed by real-time RT-PCR. Ideally a turnaround time of real-time RT-PCR requires couples of hours (Table 1) [12,50], however, the delayed deliveries of samples/results between infrastructures induce the issue of testing backlogs [51]. Due to centralized testing, a limited capacity, and excessive numbers of samples during an outbreak, sole reliance on PCR-based results have conceivably hampered the policymaking against the spread of COVID-19, leading to misjudgment of the epidemic status quo and obscurity of the disease control [51].

To address the needs, some diagnostic tests (e.g., molecular tests and antigen tests) and antibody tests using commercially-available devices and/or lab prototypes have been proposed as shown in Table 1 [12,16,21–23,31,50,52–56]. In general, molecular tests exhibit the best sensitivity/specificity, yet centralized settings and slow turnarounds deteriorate disease control. Chaibun et al. developed a portable electrochemical biosensor for molecular tests, while the LoD was not as low as the conventional PCR-based methods are [13,53]. Several antibody tests using surface plasmon-based techniques, which have an intermediate turnaround, were developed to verify a past infection;




Fig. 5. Investigation of cross-reactivity in (a) PBS and (b) artificial saliva. The data of SARS-CoV-2 N protein are retrieved from Fig. 4 and are replotted here for the comparison of cross-reactivity. Error bars represent $\pm 1\sigma$ of uncertainty measured by sensors ($n = 3$).

Table 1
Comparison of COVID-19 diagnostics.

	Molecular tests			Antibody tests			Antigen tests				
Target	RNA (RdRp, E gene, N gene)	RNA (ORF-1a, E gene)	RNA (N gene, S gene)	N Ab	N Ab, S Ab (S1, S1S2)	S Ab	N Protein	N protein	S protein (S1)	N protein, S protein (S1)	N protein
Testing specimen	NPS, NS	NPS, NS, OPS	NPS	Serum	Serum	Human plasma	NS	NPS, NS	PBS, 0.01x UTM, culture medium, NPS	DPBS, saliva	Artificial saliva
Dilution	–	–	–	No	1:1600 in PBST	1:1000 in PBS	–	–	–	1:2 in DPBS	1:1 with UTM
Methodology	Real-time RT-PCR	Real-time RT-PCR	Electro-chemical biosensor	SPR	GC-FP	LSPR	LFIA	CLEIA	Graphene-based BioFET	Glucometer (electrochemical biosensor)	EDL-gated BioFET
Portability	No, centralized	No, centralized	Yes, handheld	Yes, hand-carried	No, centralized	No, centralized	Yes, handheld	No, centralized	No, centralized	Yes, handheld	Yes, handheld
Size (mm ³)	–	–	157 × 97 × 35	175 × 155 × 55	–	–	–	–	–	76 × 48 × 16	120 × 80 × 30
Commercial Availability	Off-the-shelf device	Off-the-shelf device	Off-the-shelf device + lab-engineered testing strips	Off-the-shelf device + lab-engineered testing chips	Lab prototype	Lab prototype	Off-the-shelf device	Off-the-shelf device	Lab prototype	Off-the-shelf device + lab-engineered testing strips	Lab prototype
Highlights	–	–	Isothermal RCA	–	–	–	–	–	–	Aptamer-based competitive assay	Bluetooth-embedded, mobile-based UI
Testing time	2 hr	3 – 8 h	N/A	15 min	30 min	30 min	–	–	1 – 2 min	< 5 min	2 – 20 min
Turnaround time	> 4 hr	1 day	2 hr	60 – 90 min	~1 hr	~1 hr	15 min	2 – 4 hr	< 1 hr	~65 min	30 min
Quantification	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
LoD*	3.6 – 3.9 copy/rxn	1.8 × 10 ³ ndu/mL	1 copy/μL	1 μg/mL	< 2 ng/spot	~0.5 pM	1.58 × 10 ² TCID ₅₀ /mL	2.2 × 10 ¹ TCID ₅₀ /mL	13.1 aM (PBS) ^a 1.31 fM (UTM) ^a 16 pfu/mL (CM) ^a 242 copies/mL (CS) ^a	DPBS: 1.50 pM (N protein) ^b 1.31 pM (S protein) ^b Saliva: 5.27 pM (N protein) ^b 6.31 pM (S protein) ^b	7.44 pM (PBS) ^c 2.96 pM (AS) ^c
Reference	[12]	[52]	[53]	[54]	[55]	[56]	[22]	[23]	[31]	[16]	This Work

Ab: antibody. AS: artificial saliva. CM: culture medium. CS: clinical sample. DPBS: Dulbecco's potassium phosphate buffered saline. GC-FP: grating-coupled fluorescent plasmonics. LSPR: localized surface plasmon resonance. NPS: nasopharyngeal swab. NS: nasal swab. OPS: oropharyngeal swab. PBST: phosphate buffered saline with Tween-20. RCA: rolling circle amplification. RdRp: RNA-dependent RNA polymerase. SPR: surface plasmon resonance. TCID₅₀: median tissue culture infectious dose.

* The methods of defining LoDs: ^a the lowest concentration detected by a sensor; ^b the slope method where $LoD = 3\sigma_{blank}/slope_{calibration\ curve}$; and ^c the CLSI method, please refer to the main text in this article.

whereas the LoDs were traded off against the complexity of pre-treatments and the portability of a device [54–56]. Amongst novel methods developed for antigen testing, Seo et al. detected SARS-CoV-2 S protein using graphene-based BioFETs that was ultrasensitive and provided the LoDs (242 copies/mL in clinical samples) comparable to PCR-based methods, yet this nano device had to be measured using a bulky semiconductor analyzer in a centralized lab [31]. Singh et al. utilized an off-the-shelf glucometer with custom-engineered test strips to validate COVID-19 antigen detection in human saliva, and the LoDs reached in the range of few pM, yielding high accuracy of 100% of positive percent agreement (PPA) ($n = 16$) and 100% of negative percent agreement (NPA) ($n = 8$) in clinical testing [16]. While the 4-step pretreatment using aptamers and magnetic beads prolonged the turnaround time to ~65 min. To find a diagnostic niche, we developed a saliva-based COVID-19 antigen test using an EDL-gated BioFET system. Considering its LoD (~3 pM), a diagnosis of active infection, a quantitative result, a compatibility to a digital health using Bluetooth communication and mobile-based UI, a handheld portability ($120 \times 80 \times 30 \text{ mm}^3$), and a fast turnaround (30 min); the proposed system detecting SARS-CoV-2 N protein in artificial saliva owns a high potential to be deployed amid the frontline of diagnostic screening.

4. Conclusion

Endeavoring to fight against COVID-19, we successfully developed an antigen test of SARS-CoV-2 N protein in artificial saliva using an EDL-gated BioFET system. This portable system can be fielded for on-site COVID-19 screening since the matrix insensitivity simplifies a pre-treatment and the digital health-compatible setting eases a data outputting/collection, speeding up a turnaround time to 30 min. Surface functionalization was verified with fluorescence imaging, and sensor-to-sensor variation could root in a nonuniform coverage of surface functionalization. The detections of SARS-CoV-2 N protein were corroborated in $1 \times \text{PBS}$ and artificial saliva, indicating LoDs of 342.16 pg/mL (7.44 pM) and 136.25 pg/mL (2.96 pM), respectively. The cross-reactivity was minor, and specificity increased as the antigen concentration exceeded 4 ng/mL. The proposed system validated COVID-19 antigen tests in artificial saliva, while the assessment of clinical samples and deployments around medical infrastructures will be processed when receiving the approval/authorization from the Institutional Review Board (IRB). The testing of clinical samples collected from human saliva is expected to be more challenging since human saliva consists of extra electrolytes, enzymes, proteins, cells, mucus, etc., increasing the complexity of detections.

CRediT authorship contribution statement

Pin-Hsuan Chen: Conceptualization, Methodology, Software, Investigation, Writing – original draft, Visualization. **Chih-Cheng Huang:** Methodology, Validation, Formal analysis, Data curation, Writing – original draft, Writing – review & editing, Visualization. **Chia-Che Wu:** Methodology, Investigation. **Po-Hsuan Chen:** Investigation. **Adarsh Tripathi:** Writing – review & editing. **Yu-Lin Wang:** Conceptualization, Writing – review & editing, Supervision, Project administration, Funding acquisition.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

This work was supported, in part, by research grants from Ministry of Science & Technology, Taiwan (MOST 109–2218-E-007–017), SPARK

Program, Taiwan (109Q2901E1) and National Tsing Hua University, Taiwan (109Q2805E1, 109Q2706E1). We thank the technical support from National Nano Device Laboratories (NDL) in Hsinchu and the Center for Nanotechnology, Materials science, and Microsystems (CNMM) at National Tsing Hua University.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.snb.2022.131415.

References

- [1] S.P. and L. Magalhaes, South America Is Now Covid-19 Hot Spot, With Eight Times the World's Death Rate, Wall Str. J. (2021). <https://www.wsj.com/articles/south-america-is-now-covid-19-hot-spot-with-eight-times-the-worlds-death-rate-11624299176> (Accessed August 19, 2021).
- [2] World Health Organization, Weekly epidemiological update on COVID-19 - 17 August 2021, 2021. (<https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-17-august-2021>) (Accessed August 19, 2021).
- [3] A.E. Gorbalenya, S.C. Baker, R.S. Baric, R.J. de Groot, C. Drosten, A.A. Gulyaeva, B. L. Haagmans, C. Lauber, A.M. Leontovich, B.W. Neuman, D. Penzar, S. Perlman, L. L.M. Poon, D.V. Samborskiy, I.A. Sidorov, I. Sola, J. Ziebuhr, Coronaviridae study group of the international committee on taxonomy of viruses, the species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat. Microbiol. 5 (2020) 536–544, <https://doi.org/10.1038/s41564-020-0695-z>.
- [4] R. Wölfel, V.M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M.A. Müller, D. Niemeyer, T.C. Jones, P. Vollmar, C. Rothe, M. Hoelscher, T. Bleicker, S. Brünink, J. Schneider, R. Ehmann, K. Zwirgmaier, C. Drosten, C. Wendtner, Virological assessment of hospitalized patients with COVID-2019, Nature 581 (2020) 465–469, <https://doi.org/10.1038/s41586-020-2196-x>.
- [5] J. Hippisley-Cox, C.A. Coupland, N. Mehta, R.H. Keogh, K. Diaz-Ordaz, K. Khunti, R.A. Lyons, F. Kee, A. Sheikh, S. Rahman, J. Valabhji, E.M. Harrison, P. Sellen, N. Haq, M.G. Semple, P.W.M. Johnson, A. Hayward, J.S. Nguyen-Van-Tam, Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study, BMJ 374 (2021) n2244, <https://doi.org/10.1136/bmj.n2244>.
- [6] M.G. Thompson, E. Stenehjem, S. Grannis, S.W. Ball, A.L. Naleway, T.C. Ong, M. B. DeSilva, K. Natarajan, C.H. Bozio, N. Lewis, K. Dascomb, B.E. Dixon, R.J. Birch, S.A. Irving, S. Rao, E. Kharbanda, J. Han, S. Reynolds, K. Goddard, N. Grisel, W. F. Fadel, M.E. Levy, J. Ferdinands, B. Fireman, J. Arndorfer, N.R. Valvi, E. A. Rowley, P. Patel, O. Zerbo, E.P. Griggs, R.M. Porter, M. Demarco, L. Blanton, A. Steffens, Y. Zhuang, N. Olson, M. Barron, P. Shifflett, S.J. Schrag, J.R. Verani, A. Fry, M. Gaglani, E. Azziz-Baumgartner, N.P. Klein, Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings, N. Engl. J. Med. 385 (2021) 1355–1371, <https://doi.org/10.1056/NEJMoa2110362>.
- [7] W.J. Wiersinga, A. Rhodes, A.C. Cheng, S.J. Peacock, H.C. Prescott, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review, J. Am. Med. Assoc. 324 (2020) 782–793, <https://doi.org/10.1001/jama.2020.12839>.
- [8] S. Mallapaty, Can COVID vaccines stop transmission? Scientists race to find answers, Nature (2021), <https://doi.org/10.1038/d41586-021-00450-z>.
- [9] United States Centers for Disease Control and Prevention, COVID-19 testing overview, Cent. Dis. Control Prev. (2020). (<https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html>). accessed June 6, 2021.
- [10] United States Food and Drug Administration, Coronavirus Disease 2019 Testing Basics, FDA, 2021. (<https://www.fda.gov/consumers/consumer-updates/coronavirus-disease-2019-testing-basics>) (Accessed July 5, 2021).
- [11] A.T. Xiao, Y.X. Tong, C. Gao, L. Zhu, Y.J. Zhang, S. Zhang, Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: a descriptive study, J. Clin. Virol. 127 (2020), 104346, <https://doi.org/10.1016/j.jcv.2020.104346>.
- [12] V.M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K. Chu, T. Bleicker, S. Brünink, J. Schneider, M.L. Schmidt, D.G. Mulders, B.L. Haagmans, B. van der Veer, S. van den Brink, L. Wijsman, G. Goderski, J.-L. Romette, J. Ellis, M. Zambon, M. Peiris, H. Goossens, C. Reusken, M.P. Koopmans, C. Drosten, Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Eurosurveillance 25 (2020), 2000045, <https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045>.
- [13] R. Arnaout, R.A. Lee, G.R. Lee, C. Callahan, A. Cheng, C.F. Yen, K.P. Smith, R. Arora, J.E. Kirby, The limit of detection matters: the case for benchmarking severe acute respiratory syndrome coronavirus 2 testing, Clin. Infect. Dis. (2021), <https://doi.org/10.1093/cid/ciaa1382>.
- [14] I. Arevalo-Rodriguez, D. Buitrago-Garcia, D. Simancas-Racines, P. Zambrano-Achig, R.D. Campo, A. Ciapponi, O. Sued, L. Martinez-Garcia, A.W. Rutjes, N. Low, P.M. Bossuyt, J.A. Perez-Molina, J. Zamora, False-negative results of initial RT-PCR assays for COVID-19: a systematic review, PLoS One 15 (2020), e0242958, <https://doi.org/10.1371/journal.pone.0242958>.
- [15] Y.M. Bar-On, A. Flamholz, R. Phillips, R. Milo, SARS-CoV-2 (COVID-19) by the numbers, ELife 9 (2020), e57309, <https://doi.org/10.7554/eLife.57309>.
- [16] N.K. Singh, P. Ray, A.F. Carlin, C. Magallanes, S.C. Morgan, L.C. Laurent, E. S. Aronoff-Spencer, D.A. Hall, Hitting the diagnostic sweet spot: point-of-care

- SARS-CoV-2 salivary antigen testing with an off-the-shelf glucometer, *Biosens. Bioelectron.* 180 (2021), 113111, <https://doi.org/10.1016/j.bios.2021.113111>.
- [17] Y. Yang, M. Yang, J. Yuan, F. Wang, Z. Wang, J. Li, M. Zhang, L. Xing, J. Wei, L. Peng, G. Wong, H. Zheng, W. Wu, C. Shen, M. Liao, K. Feng, J. Li, Q. Yang, J. Zhao, L. Liu, Y. Liu, Laboratory diagnosis and monitoring the viral shedding of SARS-CoV-2 infection, *Innovation* 1 (2020), 100061, <https://doi.org/10.1016/j.xinn.2020.100061>.
 - [18] X. Mei, H.-C. Lee, K. Diao, M. Huang, B. Lin, C. Liu, Z. Xie, Y. Ma, P.M. Robson, M. Chung, A. Bernheim, V. Mani, C. Calcagno, K. Li, S. Li, H. Shan, J. Lv, T. Zhao, J. Xia, Q. Long, S. Steinberger, A. Jacobi, T. Deyer, M. Luksza, F. Liu, B.P. Little, Z. A. Fayad, Y. Yang, Artificial intelligence-enabled rapid diagnosis of patients with COVID-19, *Nat. Med.* 26 (2020) 1224–1228, <https://doi.org/10.1038/s41591-020-0931-3>.
 - [19] United States Food and Drug Administration, In Vitro Diagnostics EUAs, (2021). (<https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas>) (Accessed July 5, 2021).
 - [20] N. Ravi, D.L. Cortade, E. Ng, S.X. Wang, Diagnostics for SARS-CoV-2 detection: a comprehensive review of the FDA-EUA COVID-19 testing landscape, *Biosens. Bioelectron.* 165 (2020), 112454, <https://doi.org/10.1016/j.bios.2020.112454>.
 - [21] United States Food and Drug Administration, Individual EUAs for Antigen Diagnostic Tests for SARS-CoV-2, Vitro Diagn. EUAs - Antigen Diagn. Tests SARS-CoV-2. (2021). <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2> (Accessed July 26, 2021).
 - [22] E. Albert, I. Torres, F. Bueno, D. Huntley, E. Molla, M.Á. Fernández-Fuentes, M. Martínez, S. Poujois, L. Forqué, A. Valdivia, C. Solano de la Asunción, J. Ferrer, J. Colomina, D. Navarro, Field evaluation of a rapid antigen test (PanBioTM COVID-19 Ag rapid test device) for COVID-19 diagnosis in primary healthcare centres, *Clin. Microbiol. Infect.* 27 (2021) 472.e7–472.e10, <https://doi.org/10.1016/j.cmi.2020.11.004>.
 - [23] S. Lefever, C. Indevuyt, L. Cuyper, K. Dewaele, N. Yin, F. Cotton, E. Padalko, M. Oyaert, J. Descy, E. Cavalier, M. Van Ranst, E. André, K. Lagrou, P. Vermeersch, Comparison of the quantitative diastorin liaison antigen test to reverse transcription-PCR for the diagnosis of COVID-19 in symptomatic and asymptomatic outpatients, *J. Clin. Microbiol.* 59 (2021) e00374–21, <https://doi.org/10.1128/JCM.00374-21>.
 - [24] O. Fakheran, M. Dehghannejad, A. Khademi, Saliva as a diagnostic specimen for detection of SARS-CoV-2 in suspected patients: a scoping review, *Infect. Dis. Poverty* 9 (2020) 100, <https://doi.org/10.1186/s40249-020-00728-w>.
 - [25] L. Li, C. Tan, J. Zeng, C. Luo, S. Hu, Y. Peng, W. Li, Z. Xie, Y. Ling, X. Zhang, E. Deng, H. Xu, J. Wang, Y. Xie, Y. Zhou, W. Zhang, Y. Guo, Z. Liu, Analysis of viral load in different specimen types and serum antibody levels of COVID-19 patients, *J. Transl. Med.* 19 (2021) 30, <https://doi.org/10.1186/s12967-020-02693-2>.
 - [26] Y. Pan, D. Zhang, P. Yang, L.L.M. Poon, Q. Wang, Viral load of SARS-CoV-2 in clinical samples, *Lancet Infect. Dis.* 20 (2020) 411–412, [https://doi.org/10.1016/S1473-3099\(20\)30113-4](https://doi.org/10.1016/S1473-3099(20)30113-4).
 - [27] W. Wang, Y. Xu, R. Gao, R. Lu, K. Han, G. Wu, W. Tan, Detection of SARS-CoV-2 in different types of clinical specimens, *J. Am. Med. Assoc.* 323 (2020) 1843–1844, <https://doi.org/10.1001/jama.2020.3786>.
 - [28] L. Azzi, G. Carcano, F. Gianfagna, P. Grossi, D.D. Gasperina, A. Genoni, M. Fasano, F. Sessa, L. Tettamanti, F. Carinci, V. Maurino, A. Rossi, A. Tagliabue, A. Baj, Saliva is a reliable tool to detect SARS-CoV-2, *J. Infect.* 81 (2020) e45–e50, <https://doi.org/10.1016/j.jinf.2020.04.005>.
 - [29] V.C.C. Cheng, S.-C. Wong, J.H.K. Chen, C.C.Y. Yip, V.W.M. Chuang, O.T.Y. Tsang, S. Sridhar, J.F.W. Chan, P.-L. Ho, K.-Y. Yuen, Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong, *Infect. Control Hosp. Epidemiol.* 41 (2020) 493–498, <https://doi.org/10.1017/ice.2020.58>.
 - [30] J. Zhu, J. Guo, Y. Xu, X. Chen, Viral dynamics of SARS-CoV-2 in saliva from infected patients, *J. Infect.* 81 (2020) e48–e50, <https://doi.org/10.1016/j.jinf.2020.06.059>.
 - [31] G. Seo, G. Lee, M.J. Kim, S.-H. Baek, M. Choi, K.B. Ku, C.-S. Lee, S. Jun, D. Park, H. G. Kim, S.-J. Kim, J.-O. Lee, B.T. Kim, E.C. Park, S.I. Kim, Rapid Detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor, *ACS Nano* 14 (2020) 5135–5142, <https://doi.org/10.1021/acsnano.0c02823>.
 - [32] K.-I. Chen, B.-R. Li, Y.-T. Chen, Silicon nanowire field-effect transistor-based biosensors for biomedical diagnosis and cellular recording investigation, *Nano Today* 6 (2011) 131–154, <https://doi.org/10.1016/j.nantod.2011.02.001>.
 - [33] C.-C. Huang, G.-Y. Lee, J.-I. Chyi, H.-T. Cheng, C.-P. Hsu, Y.-R. Hsu, C.-H. Hsu, Y.-F. Huang, Y.-C. Sun, C.-C. Chen, S.-S. Li, J. Andrew Yeh, D.-J. Yao, F. Ren, Y.-L. Wang, AlGaN/GaN high electron mobility transistors for protein–peptide binding affinity study, *Biosens. Bioelectron.* 41 (2013) 717–722, <https://doi.org/10.1016/j.bios.2012.09.066>.
 - [34] Y.-R. Hsu, Y.-W. Kang, J.-Y. Yang, G.-Y. Lee, J.-I. Chyi, C. Chang, C.-C. Huang, C.-P. Hsu, T. Huang, Y.-F. Huang, Y.-C. Sun, C.-H. Hsu, C.-C. Chen, S.-S. Li, J.A. Yeh, D.-J. Yao, F. Ren, Y.-L. Wang, Investigation of C-terminal domain of SARS nucleocapsid protein–duplex DNA interaction using transistors and binding-site models, *Sens. Actuators B Chem.* 193 (2014) 334–339, <https://doi.org/10.1016/j.snb.2013.11.087>.
 - [35] K. Maehashi, Y. Ohno, K. Matsumoto, Utilizing research into electrical double layers as a basis for the development of label-free biosensors based on nanomaterial transistors, *Nanobiosens. Dis. Diagn.* 5 (2015) 1–13, <https://doi.org/10.2147/NDD.S40316>.
 - [36] T. Sakata, Y. Matsuse, In situ electrical monitoring of cancer cells invading vascular endothelial cells with semiconductor-based biosensor, *Genes Cells* 22 (2017) 203–209, <https://doi.org/10.1111/gtc.12473>.
 - [37] H.-L. Cheng, C.-Y. Fu, W.-C. Kuo, Y.-W. Chen, Y.-S. Chen, Y.-M. Lee, K.-H. Li, C. Chen, H.-P. Ma, P.-C. Huang, Y.-L. Wang, G.-B. Lee, Detecting miRNA biomarkers from extracellular vesicles for cardiovascular disease with a microfluidic system, *Lab Chip* 18 (2018) 2917–2925, <https://doi.org/10.1039/c8lc00386f>.
 - [38] Q. Li, N. Lu, L. Wang, C. Fan, Advances in nanowire transistor-based biosensors, *Small Methods* 2 (2018), 1700263, <https://doi.org/10.1002/smt.201700263>.
 - [39] T.-Y. Tai, A. Sinha, I. Sarangadharan, A.K. Pulikkathodi, S.-L. Wang, G.-Y. Lee, J.-I. Chyi, S.-C. Shiesh, G.-B. Lee, Y.-L. Wang, Design and demonstration of tunable amplified sensitivity of algal/gan high electron mobility transistor (hemt)-based biosensors in human serum, *Anal. Chem.* 91 (2019) 5953–5960, <https://doi.org/10.1021/acs.analchem.9b00353>.
 - [40] Y.-H. Chen, A.K. Pulikkathodi, Y.-D. Ma, Y.-L. Wang, G.-B. Lee, A microfluidic platform integrated with field-effect transistors for enumeration of circulating tumor cells, *Lab Chip* 19 (2019) 618–625, <https://doi.org/10.1039/C8LC01072B>.
 - [41] D. Sung, J. Koo, A review of BioFET's basic principles and materials for biomedical applications, *Biomed. Eng. Lett.* 11 (2021) 85–96, <https://doi.org/10.1007/s13534-021-00187-8>.
 - [42] C.-H. Chu, I. Sarangadharan, A. Regmi, Y.-W. Chen, C.-P. Hsu, W.-H. Chang, G.-Y. Lee, J.-I. Chyi, C.-C. Chen, S.-C. Shiesh, G.-B. Lee, Y.-L. Wang, Beyond the Debye length in high ionic strength solution: direct protein detection with field-effect transistors (FETs) in human serum, *Sci. Rep.* 7 (2017) 5256, <https://doi.org/10.1038/s41598-017-05426-6>.
 - [43] L. Mousavizadeh, S. Ghasemi, Genotype and phenotype of COVID-19: Their roles in pathogenesis, *J. Microbiol. Immunol. Infect.* 54 (2021) 159–163, <https://doi.org/10.1016/j.jmii.2020.03.022>.
 - [44] D.A. Armbruster, T. Pry, Limit of blank, limit of detection and limit of quantitation, *Clin. Biochem. Rev.* 29 (2008) S49–S52.
 - [45] J.F. Pierson-Perry, J.E. Vaks, A.P. Durham, C. Fischer, C. Gutenbrunner, D. Hillyard, M.V. Kondratovich, P. Ladwig, R.A. Middleberg, EP17A2 Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures, Second ed., Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2012. (<https://clsi.org/standards/products/method-evaluation/documents/ep17/>).
 - [46] E. Pasomsub, S.P. Watcharananan, K. Boonyawat, P. Janchompoo, G. Wongtabtim, W. Suksuwan, S. Sungkanuparph, A. Phuphuakrat, Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study, *Clin. Microbiol. Infect.* 27 (2021) 285.e1–285.e4, <https://doi.org/10.1016/j.cmi.2020.05.001>.
 - [47] B.M. Berenger, J.M. Conly, K. Fonseca, J. Hu, T. Louie, A.R. Schneider, T. Singh, W. Stokes, L. Ward, N. Zelyas, Saliva collected in universal transport media is an effective, simple and high-volume amenable method to detect SARS-CoV-2, *Clin. Microbiol. Infect.* 27 (2021) 656–657, <https://doi.org/10.1016/j.cmi.2020.10.035>.
 - [48] A.L.M. de Sousa, R.R. Pinheiro, J.F. Araújo, D.A.A. de Azevedo, R.M. Peixoto, A. Andrioli, S.T. da Cruz Silva Bezerra, M.F. da Silva Teixeira, Sodium dodecyl sulfate as a viral inactivator and future perspectives in the control of small ruminant lentiviruses, *Arq. Inst. Biol.* 86 (2019), <https://doi.org/10.1590/1808-1657000752018>.
 - [49] B.J. Tromberg, T.A. Schwetz, E.J. Pérez-Stable, R.J. Hodes, R.P. Woychik, R. A. Bright, R.L. Fleurence, F.S. Collins, Rapid scaling up of Covid-19 diagnostic testing in the United States — the NIH RADx initiative, *N. Engl. J. Med.* (2020), <https://doi.org/10.1056/NEJMs2022263>.
 - [50] United States Food and Drug Administration, In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2, FDA. (2021). (<https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2>) (Accessed July 31, 2021).
 - [51] H. Wu, Taiwan struggles with testing backlog amid largest outbreak, *Assoc. Press News*, 2021. (<https://apnews.com/article/taiwan-coronavirus-pandemic-business-health-c12fc8276820e18751d85e52dcdb882>). accessed July 31, 2021.
 - [52] cobas® SARS-CoV-2, 2021. (<https://www.fda.gov/media/136049/download>).
 - [53] T. Chaibun, J. Puenpa, T. Ngamdee, N. Boonapatcharoen, P. Athamanolap, A. P. O'Mullane, S. Vongpunsawad, Y. Poovorawan, S.Y. Lee, B. Lertanantawong, Rapid electrochemical detection of coronavirus SARS-CoV-2, *Nat. Commun.* 12 (2021) 802, <https://doi.org/10.1038/s41467-021-21121-7>.
 - [54] A. Djaileb, B. Charron, M.H. Jodavilamy, V. Thibault, J. Coutu, K. Stevenson, S. Forest, L.S. Live, D. Boudreau, J.N. Pelletier, J.-F. Masson, A rapid and quantitative serum test for SARS-CoV-2 antibodies with portable surface plasmon resonance sensing, *ChemRxiv Camb. Camb. Open Engag.* 2020 (2020), <https://doi.org/10.26434/chemrxiv.12118914.v1>.
 - [55] N.C. Cady, N. Tokranova, A. Minor, N. Nikvand, K. Strle, W.T. Lee, W. Page, E. Guignon, A. Pilar, G.N. Gibson, Multiplexed detection and quantification of human antibody response to COVID-19 infection using a plasmon enhanced biosensor platform, *Biosens. Bioelectron.* 171 (2021), 112679, <https://doi.org/10.1016/j.bios.2020.112679>.
 - [56] R. Funari, K.-Y. Chu, A.Q. Shen, Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip, *Biosens. Bioelectron.* 169 (2020), 112578, <https://doi.org/10.1016/j.bios.2020.112578>.



Pin-Hsuan Chen received the B.S. degree in biomedical engineering and environmental sciences from National Tsing Hua University, Hsinchu, Taiwan, in 2019, and the M.S. degree in power mechanical engineering from National Tsing Hua University, Hsinchu, Taiwan, in 2021. Her principal research interests are electrochemistry and biosensors. She worked on the development of a rapid screening biosensor platform that detected SARS-COV-2 virus.



Dr. Po-Hsuan Chen received the B.S. degree in biological science and technology from China Medical University, Taichung, Taiwan in 2009, the Ph.D. degree in molecular biology from National Chung Cheng University, Chia-Yi, Taiwan, in 2016. His research interests include molecular biology, cancer biology, cell biology, biochemistry, and semiconductor-based bio-sensors.



Dr. Chih-Cheng Huang received the B.S. degree in materials science and engineering from National Taiwan University, Taipei, Taiwan, in 2010, the M.S. degree in nanoengineering from National Tsing Hua University, Hsinchu, Taiwan, in 2012, and the Ph.D. degree in materials science from the University of California San Diego, La Jolla, CA, USA, in 2020. He is currently a postdoctoral research fellow at National Tsing Hua University. His research interests include nanomagnetism, PoC diagnostics, next-generation biosensing techniques, and proteomics. Dr. Huang has been a member of the American Chemical Society (ACS) since 2012.



Adarsh Tripathi received his Integrated Masters degree (5 years integrated program) in Biotechnology from Vellore Institute of Technology, Vellore, Tamil Nadu, India in 2014. He was a Ph.D. student in National Tsing Hua University. His research interests include genetic engineering, proteomics and biosensing.



Chia-Che Wu received the B.S. degree in biological science and technology from China Medical University, Taichung, Taiwan in 2018, and the M.S. degree in pharmacology from National Taiwan University, Taipei, Taiwan, in 2020. He is currently a master student at National Tsing Hua University. His research focuses on electrochemical biosensing and its application on early diagnoses.



Dr. Yu-Lin Wang received his B.S. degree in chemistry from Tunghai University and M.S. degree from National Taiwan University, in 1993 and 1995, respectively. He had worked in semiconductor industry from 1997 to 2006. He received his Ph. D. in materials science and engineering from University of Florida, in 2009. He is currently a Professor in the Institute of NanoEngineering and Microsystems, Department of Power Mechanical Engineering, at National Tsing Hua University, Hsinchu, Taiwan. His research interests are semiconductor-based sensors and the device for medical use and personal healthcare. His team has won several awards in recent years including the Top 10 pioneering technology worldwide

selected by Google-X in 2016, Merit of Asia Pacific ICT Alliance in 2016, Gold Medal by Spintech Inc. in 2018, Silver Medal by uTAS in 2018, and Silver Medal by EpiStar Inc. in 2019.